Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )

13.61 +0.23 (+1.72%)
Streaming Delayed Price Updated: 2:39 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 432,132
Open 13.34
Bid (Size) 13.61 (1)
Ask (Size) 13.64 (9)
Prev. Close 13.38
Today's Range 13.25 - 13.75
52wk Range 4.650 - 18.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
Via Benzinga

Performance

YTD
+143.91%
+143.91%
1 Month
-18.94%
-18.94%
3 Month
+6.25%
+6.25%
6 Month
+54.66%
+54.66%
1 Year
+187.74%
+187.74%

More News

Read More
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
Via Benzinga
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
Via Investor's Business Daily
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
Via Benzinga
Where ARS Pharmaceuticals Stands With Analysts
Via Benzinga
Analyst Ratings For ARS Pharmaceuticals
Via Benzinga
Looking Into ARS Pharmaceuticals's Recent Short Interest
Via Benzinga
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
Via Benzinga
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Via Benzinga
Exposures Product Safety
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.